Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled. J Virol, 80(10), 4717-28. presented at the 2006 May. doi:10.1128/JVI.80.10.4717-4728.2006. (2006).
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-95. presented at the 2008 May 23. doi:10.1016/j.vaccine.2008.02.071. (2008).
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses, 26(8), 933-42. presented at the 2010 Aug. doi:10.1089/aid.2009.0242. (2010).
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One, 5(9), e12873. presented at the 2010 Sep 21. doi:10.1371/journal.pone.0012873. (2010).
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis, 201(5), 720-9. presented at the 2010 Mar. doi:10.1086/650492. (2010).
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One, 7(8), e41936. presented at the 2012. doi:10.1371/journal.pone.0041936. (2012).
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS One, 10(5), e0125954. presented at the 2015. doi:10.1371/journal.pone.0125954. (2015).
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev, 3, 16061. presented at the 2016. doi:10.1038/mtm.2016.61. (2016).
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis, 215(1), 95-104. presented at the 2017 Jan 01. doi:10.1093/infdis/jiw500. (2017).